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Abstract
Introduction: TNF-like weak inducer of apoptosis (TWEAK) has been proposed as a mediator of inflammation and
bone erosion in rheumatoid arthritis (RA). This study aimed to investigate TWEAK and TWEAK receptor (Fn14)
expression in synovial tissue from patients with active and inactive rheumatoid arthritis (RA), osteoarthritis (OA) and
normal controls and assess soluble (s)TWEAK levels in the synovial fluids from patients with active RA and OA.
Effects of sTWEAK on osteoclasts and osteoblasts were investigated in vitro.
Methods: TWEAK and Fn14 expression were detected in synovial tissues by immunohistochemistry (IHC). Selected
tissues were dual labelled with antibodies specific for TWEAK and lineage-selective cell surface markers CD68,
Tryptase G, CD22 and CD38. TWEAK mRNA expression was examined in human peripheral blood mononuclear cells
(PBMC) sorted on the basis of their expression of CD22. sTWEAK was detected in synovial fluid from OA and RA
patients by ELISA. The effect of sTWEAK on PBMC and RAW 264.7 osteoclastogenesis was examined. The effect of
sTWEAK on cell surface receptor activator of NF Kappa B Ligand (RANKL) expression by human osteoblasts was
determined by flow cytometry.
Results: TWEAK and Fn14 expression were significantly higher in synovial tissue from all patient groups compared
to the synovial tissue from control subjects (P < 0.05). TWEAK was significantly higher in active compared with
inactive RA tissues (P < 0.05). TWEAK expression co-localised with a subset of CD38
+ plasma cells and with CD22
+
B-lymphocytes in RA tissues. Abundant TWEAK mRNA expression was detected in normal human CD22
+ B cells.
Higher levels of sTWEAK were observed in synovial fluids isolated from active RA compared with OA patients.
sTWEAK did not stimulate osteoclast formation directly from PBMC, however, sTWEAK induced the surface
expression of RANKL by human immature, STRO-1
+ osteoblasts.
Conclusions: The expression of TWEAK by CD22
+ B cells and CD38
+ plasma cells in RA synovium represents a
novel potential pathogenic pathway. High levels of sTWEAK in active RA synovial fluid and of TWEAK and Fn14 in
active RA tissue, together with the effect of TWEAK to induce osteoblastic RANKL expression, is consistent with
TWEAK/Fn14 signalling being important in the pathogenesis of inflammation and bone erosion in RA.
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TWEAK (TNF-like weak inducer of apoptosis) is a
recently described member of the TNF superfamily. It is
reported to exert a variety of biological effects through
ligation with its receptor, Fn14. The biological effects of
TWEAK include induction of pro-inflammatory cyto-
kines, modulation of the immune response and angio-
genesis, stimulation of apoptosis and regulation of tissue
repair and regeneration [1,2]. The pro-inflammatory
effects of TWEAK/Fn14 signalling are mediated by sev-
eral signalling cascades, including NF-B and the
mitogen-activated protein kinases (MAPK), ERK1/2,
JNK1/2 and p38 [3]. TWEAK induces the production of
a large number of pro-inflammatory molecules, such as
matrix metalloproteinase (MMP1), IL-6, IL-8, MCP-I
and Regulated upon Activation Normal T Cell
Expressed and Secreted (RANTES) by synoviocytes and
fibroblasts, as well as ICAM-1, E-selectin, IL-8, and
MCP-1 by endothelial cells [4]. The majority of these
cytokines are induced by TWEAK/Fn14 induction of the
NF-b signalling pathway [3,5]. The pro-inflammatory
effects of TWEAK are seen in various cell types includ-
ing glomerular mesangial cells [6], human umbilical vein
endothelial cells (HUVEC) [7], human gingival fibro-
blasts [8], human dermal fibroblasts, synoviocytes [9],
chondrocytes, and fibroblasts [2].
Recent reports from us [10] and others [11] are consis-
tent with TWEAK being a key mediator of joint pathol-
ogy in murine RA models and in human RA [12,13].
Specifically, recombinant TWEAK enhanced the produc-
tion of MCP-1 and MIP-2 by synovial cells from collagen
induced arthritis (CIA) mice in vitro, while the addition
of TWEAK monoclonal antibody ameliorated paw swel-
ling, synovial proliferation and inflammatory cell accu-
mulation in CIA [10,11]. A role for TWEAK has been
described in human RA, where TWEAK induced the pro-
liferation of synovial fibroblasts and increased the pro-
duction of inflammatory cytokines and chemokines, as
well as the expression of ICAM-1 [12]. High serum levels
of TWEAK, TNF-a and IL-6 were seen in RA patients as
compared to normal controls [13]. Moreover, serum
TWEAK levels correlated with the disease activity score
(DAS28) in RA patients and high serum TWEAK levels
demonstrated a correlation with short-term response to
etanercept treatment [13]. Higher levels of TWEAK were
found in RA compared to psoriatic synovium [14]. In the
current study we examine TWEAK expression in a larger
group of patient-derived samples that encompassed
active and inactive RA, osteoarthritic (OA) and normal
patients. In addition, levels of soluble (s) TWEAK in the
synovial fluids of active RA compared with OA patients
were determined.
Pertinent to the pathogenesis of cartilage and bone
loss in RA, TWEAK has been demonstrated to promote
bone and cartilage destruction through inhibition of
chondrogenesis, osteogenesis and the induced produc-
tion of matrix metalloproteinase (MMP)-3 [10,15]. We
have recently described a role for TWEAK in human
osteoblast differentiation [16] and Polek et al. have pro-
posed its role in osteoclastogenesis [17]. In a more
recent study, we demonstrated a significant relationship
between serum TWEAK levels and bone erosion mar-
kers in patients with bone destructive multiple myeloma
[18]. In addition, we have shown that TWEAK, alone
and together with TNF-a,i n d u c e st h ee x p r e s s i o nb y
osteoblasts and osteocytes, in vitro and in ex vivo bone,
of the bone formation inhibitor, sclerostin, via a MAPK-
dependent pathway [16] suggesting a means by which
TWEAK may inhibit bone formation during inflamma-
tory bone remodeling. These findings suggest that
TWEAK may modulate the bone erosion associated
with several diseases, such as rheumatoid arthritis (RA)
and multiple myeloma. The present study extends these
findings by investigating the effect of sTWEAK on
osteoclastogenesis and furthermore the effect of
sTWEAK on osteoblasts in vitro.
Materials and methods
Patients
This study was approved by the Human Ethics Commit-
tees of the University of Adelaide and The Repatriation
General Hospital, and informed consent was obtained
from all patients and healthy donors. RA patients ful-
filled the 1987 revised criteria of the American College
of Rheumatology (ACR) [19]. OA patients fulfilled the
criteria by Altman and colleagues [20]. All patients with
active RA had joint inflammation and patients with
inactive RA were in remission after successful disease
modifying anti-rheumatic drug (DMARD) treatment.
Normal synovial tissues were obtained as previously
described [21]. Synovial tissue was obtained from 39
patients (10 active RA, 9 inactive RA, 10 OA patients
and 10 normal subjects) at the time of knee arthroscopy
or total knee replacement surgery (OA patients) at the
Rheumatology Unit, Repatriation General Hospital,
South Australia. Characteristics of patients for IHC are
summarised in Table 1.
Synovial fluid samples for ELISA were obtained from
17 active RA (5 female/12 male) and 16 OA (7 female/9
male) subjects. The mean age (± SEM) of the OA group
was 66.40 ± 3.18 and of the active RA group was
63.19 ± 3.78.
Immunohistochemical detection of TWEAK
TWEAK was detected using the previously described
IHC method [22,23]. Briefly, tissue sections (5 μm) were
deparaffinised, pre-treated with proteinase-K to unmask
the antigen and treated with sodium azide in PBS (0.1%
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dase. Sections were then incubated overnight with
mouse anti-human TWEAK monoclonal antibody
(MAb), P2D10 (15 μg/ml) [6]. Secondary antibody
(HRP-conjugated goat anti-mouse IgG, DAKO, Botany,
NSW, Australia) was then added, followed by HRP-
conjugated swine anti-goat IgG (Biosource, Camarillo,
CA, USA). The colour reaction was developed using
AEC (3,9 aminoethylcarbazole from Sigma, St. Louis,
MO, USA). Counterstaining was performed using Harris
haematoxylin and lithium carbonate. An isotype-
matched, non-binding control antibody (1D4.5, isotype
IgG2a) at an identical IgG concentration or omission of
the primary antibody, was used as a negative control.
Tonsil tissues obtained at surgery were used as controls
for lymphocytic staining.
Immunohistochemical detection of Fn14
Fn14 was detected using previously published methods
[24]. Briefly, sections were deparaffinised and pre-treated
with 10 mM sodium citrate buffer (pH 6.0) at 95°C for
20 minutes. Endogenous peroxidase was then blocked
using 0.3% v/v H2O2 in methanol solution. Blocking
serum was applied, according to the manufacturer’s
instructions (Vectastain Universal Elite ABC kit, Vector
Laboratories, Burlingame, CA, USA). Sections were then
incubated with anti-human Fn14 MAb (ITEM1; Biole-
gend, San Diego, CA, USA) at 20 μg/ml overnight.
Appropriate biotinylated secondary antibody was then
added in the presence of 10% normal horse serum. Sec-
tions were then treated with avidin-biotin complex
reagent before being stained with 3,3’ Diaminobenzidine
(DAB) (Vector Labs). Counter-staining and isotype-
matched negative controls were performed as above for
TWEAK staining.
Dual immunohistochemistry
Double staining was performed to identify specific cell
types expressing TWEAK using a previously published
method [23]. Anti-TWEAK antibody was combined
with MAbs for human cell surface markers: CD68
(macrophage; clone KP-1, Dako), CD22 (B lymphocyte;
MAB1968, R&D Systems, Minneapolis, MN, USA),
Tryptase G3 (mast cell; Cell Marque, Rocklin, CA, USA)
and CD38 (plasma cells, BD Biosciences, Franklin Lakes,
NJ, USA). After the single immunoperoxidase staining
described above, the colour reaction was developed
using an alkaline phosphatase reaction. Normal donkey
serum (20% in PBS) was used to block non-specific
binding, followed by incubation with cell surface marker
antibodies overnight. Sections were incubated with AP-
conjugated donkey anti-mouse IgG (Jackson Immuno
Research, West Grove, PA, USA) as secondary antibody
followed by incubation with mouse APAAP IgG (Dako,
Botany, NSW, Australia). Colour was developed using
a Fast Blue substrate. Using this method, immunoperox-
idase stained cells were red, immuno-alkaline phospha-
tase stained cells were blue, while cells with
co-expression were purple.
Quantification of immunohistochemical staining
A semi-quantitative (SQA) scoring method was used to
assess single immunohistochemical labelling, using a
validated scoring system [22]. SQAs were analysed sta-
tistically by SPSS 11.5 software (SPSS Inc. Chicago, IL,
USA) using non-parametric analysis. A P-value of less
than 0.05 was considered to be significant.
Detection of TWEAK mRNA in CD22
+ B Cells
Human peripheral blood mononuclear cells (PBMC)
were prepared from normal buffy coat blood packs
(Australian Red Cross Society, Adelaide, SA) on Ficoll
gradients, as previously described [25]. CD22-expressing
cells were isolated by fluorescence activated cell sorting
(FACS) after staining with a mouse anti-human CD22
monoclonal antibody directly conjugated to phycoery-
thrin (anti-human CD22RPE, Clone 4KB128, Dako,
Golstrup, Denmark), by a method essentially described
Table 1 Demographic of patient for IHC TWEAK and Fn14 in synovial tissues
Control Active RA Inactive RA OA
Gender (Female/Male) 4/6 6/4 3/6 3/7
Mean Age (years) (range) 40.2 (25 to 58) 69.2 (31 to 86) 72.33 (60 to 79) 69.3 (55 to 77)
Disease duration (months) (range) NA 3.1 (2 to 6) 21.77 (7 to 36) NA
Rheumatoid Factor NA 6/10 5/9 NA
Erosions NA 2/10 2/9 NA
C-Reactive protein median (mg/ml) (range) NA 67.5 (27.0 to 307.0) 6 (2.0 to 26.0) NA
Treatment NA 9 NSAIDs 5 im gold 6 NSAIDs
1 prednisolone 2 methotrexate 3 NSAIDs
1sulphasalazine 1 panadeine
1 plaquenil
NA, not available; NSAIDs: non steroidal anti-inflammatory drugs.
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+ or CD22
- cells were pelleted by
centrifugation and resuspended in Trizol reagent. Total
RNA and complementary DNA (cDNA) were prepared,
and real-time reverse transcription polymerase chain
reaction (RT-PCR) performed for the expression of
TWEAK mRNA, as previously described [16].
Detection of sTWEAK in synovial fluids
sTWEAK levels were measured following the manufac-
turer’s instructions using a TWEAK instant ELISA kit
(Bender MedSystem, Burlingame, CA, USA). Briefly,
samples were added in duplicate to a 96-microwell
plate, which had been pre-coated with antibody, capture
antibody and secondary antibody and colour was devel-
oped using tetramethylbenzidine (TMB) substrate. The
absorbance was read at 450 nm using Multiskan Ascent
plate reader (Thermo Labsystems, Helsinki, Finland).
A standard curve was generated from the control sera
provided with the kit. The difference between the mean
levels of sTWEAK in the two groups was analysed using
an independent sample t test. A P-value of less than
0.05 was considered to be significant.
Osteoclastogenesis assays in human PBMC and RAW
264.7 cells
Human CD14
+ PBMC were isolated by FACS, as
described previously in detail [25]. The isolated cells were
plated at 2 × 10
5 cells/well into a 96-microwell plate for
tartrate resistant acid phosphatase (TRAP) staining or on
whale dentine slices for resorption assays. Cells were cul-
tured in aMEM medium containing 10% foetal calf serum
(FCS) and 10 nM dexamethasone (Fauldings, Adelaide,
SA, Australia) and rhM-CSF (25 ng/ml; Millipore, Teme-
cula, CA, USA). Cultures received additional rhTWEAK
and/or rhRANKL as indicated and were fed every three
days. TRAP activity was assessed at 9 days and resorption
was assessed by scanning electron microscopy (SEM) after
14 days, as described previously [25].
Murine RAW 264.7 cells were plated at 1 × 10
5 cells/
well into 96-well plates, in the presence or absence of
recombinant human (rh) Receptor Activator of Nuclear
factor Kappa-B Ligand (RANKL) (100 ng/ml) (Millipore)
and/or rhTWEAK (10 to 800 ng/ml). Cells were cul-
tured for up to seven days in a-MEM medium contain-
ing 10% FCS and 10 nM 1a,25-dihydroxyvitamin D3
(1,25 D) [26] then stained for TRAP using a commercial
kit (Sigma) at Day 7.
Osteoblast assays
Human primary osteoblasts were cultured from cancellous
bone samples obtained from patients undergoing total hip
replacement surgery, as described previously [16]. Cells
(10
5/well) were seeded into wells of a six-well plate and
cultured overnight in aMEM medium containing 10% v/v
FCS. Cells were then cultured untreated or treated with
recombinant human TWEAK (50 ng/ml) for three days
[16]. Cells were enzymically removed and stained for
STRO-1 [27] as previously described [28], and RANKL
(MAB6261, R&D Systems) using an anti-mouse IgM-PE
and anti-mouse IgG-FITC conjugate, respectively. Isotype-
matched negative control antibodies 1A6.12 (IgM) and
1B5 (IgG1) were used to determine the level of back-
ground fluorescence for each fluorochrome and the com-
pensation settings. Stained cells were analysed on a
FACStar
PLUS flow cytometer (Becton Dickinson, Sunny-
vale, CA, USA). The percentages of cells positive for either
or both STRO-1 and RANKL were calculated.
Results
Immunohistochemistry
Immunohistochemical staining demonstrated that
TWEAK was expressed at significantly higher levels in
synovial tissue from active RA, inactive RA and OA
patients (Figure 1A-C, respectively) compared to normal
Figure 1 Immuhistochemical staining of TWEAK and Fn14 in
various synovia. Expression of TWEAK (indicated by red, left) and
Fn14 (indicated by brown, right) in active RA (A, E), inactive RA (B,
F), OA (C, G) and normal synovial tissue (D, H). Insert in panel A is
TWEAK expression by cells with resembling plasma cell-like
morphology. All sections were counterstained with haematoxylin.
Images were obtained using a 20× objective.
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cytoplasmic TWEAK had either a macrophage-like mor-
phology and were scattered in the synovial lining or
appeared to be lymphocytes in the sub-lining region of
active RA specimens. Significantly higher levels of
TWEAK staining were observed in active RA compared
to inactive RA synovial tissue (P < 0.05, Figures 1A, B
and 2). In OA tissues (Figure 1C), TWEAK expression
was confined mainly to the lining region with much
weaker staining intensity compared to active RA syno-
vial tissue. In addition, TWEAK was weakly expressed
by cells lining the blood vessels, particularly in the syno-
vial tissue from normal controls (Figure 1D).
Fn14 was highly expressed in synovia from active RA
patients (Figure 1E) compared to other groups (Figure
1F-H). There was a statistically significant difference
between Fn14 expression in normal tissue compared to
diseased groups (Figure 2), but not between active RA
and inactive RA groups. There was a strong correlation
between the relative expression of TWEAK and Fn14
in synovial tissues (Kendall tau_ b test, r =0 . 4 4 3 ,
P = 0.001).
Cell types expressing TWEAK and Fn14
In the active RA tissues a subset of the CD68-positive
cells (macrophages) weakly expressed TWEAK (Figure
3A). In addition there is a subset of TWEAK positive
c e l l sw h i c ha r ep o s i t i v ef o rt h ep l a s m ac e l lm a r k e r ,
CD38 (Figure 3B). However, the majority of cells
strongly expressing TWEAK were positive for the B
lymphocyte marker, CD22 (Figure 3C, D). TWEAK was
not expressed by cells staining positive for the mast cell
marker, Tryptase G, in any of the patient tissues (data
not shown). On close inspection, some of the cells
expressing TWEAK contained multiple nuclei (arrowed
in Figure 3E). In the control tonsil tissue TWEAK was
expressed by only a few B lymphocytes (Figure 3F). Due
to the staining conditions required for the Fn14 MAb,
dual labelling studies with this antibody were not possi-
ble. The majority of cells expressing Fn14 were similar
in morphology to those expressing TWEAK (monocytes
or lymphocytes). Close examination of the cells staining
for Fn14 showed that some of these cells were also mul-
tinucleated cells (Figure 3G). Cells lining the small
blood vessels also expressed Fn14. This was seen to
some extent in all the tissues but was particularly pro-
minent in the active RA tissue (Figure 3H).
Given that the clone used to detect TWEAK, P2D10,
is function neutralising [6], it is unlikely that TWEAK-
positivity was due to Fn14-positive cells binding soluble
TWEAK. However, to confirm that B cells are a poten-
tial source of TWEAK, CD22-expressing or non-
expressing cells were isolated by FACS and real-time
RT-PCR performed for TWEAK mRNA expression. As
s h o w ni nF i g u r e4 ,C D 2 2
+ PBMC from two healthy
volunteers expressed abundant TWEAK mRNA, relative
to that of the housekeeping gene, GAPDH, and did so
to a greater extent than the CD22
- fraction, consisting
largely of T-cells and monocytes.
TWEAK in synovial fluids from RA and OA
While not statistically significant, there was a trend (P =
0.079) for higher measurable levels of TWEAK protein
in active RA synovial fluid (1,226 ± 235 pg/ml) than in
the OA samples (713 ± 134 pg/ml) (Figure 5).
Effect of soluble TWEAK on osteoclastogenesis in vitro
Recombinant human (rh) TWEAK at concentrations as
high as 800 ng/ml in the presence of M-CSF did not sti-
mulate osteoclast differentiation from unfractionated
Figure 2 SQA analysis of TWEAK and Fn14. TWEAK and Fn14 expression in various synovial tissues as expressed by mean SQA ± SEM.
Significant differences (P < 0.05) are indicated by * compared to normal and F compared to inactive RA synovial tissue.
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+ human
PBMC (not shown). Furthermore, RANKL/M-CSF
osteoclastogenesis was inhibited rather than stimulated
by rhTWEAK (Figure 6) as assessed by both TRAP
staining and resorption pit formation on dentine slices
(Figure 6). Identical results were obtained when murine
RAW 264.7 cells were used as osteoclast precursors
(data not shown).
Effects of soluble TWEAK on cell surface RANKL
expression
Treatment of human primary osteoblasts with
rhTWEAK for three days resulted in the increased cell
Figure 3 Dual immunostaining for TWEAK and cell lineage
markers and cells expressing Fn14. Dual immunostaining for
TWEAK (red) and CD68 (blue) in inflamed synovial tissue from a
patient with active RA (A). Dual immunostaining for TWEAK (red)
with CD38 (blue) with co-expression of TWEAK and CD38 (purple)
indicated by arrow (B). C) and D) Dual immunostaining for TWEAK
(red) with CD22 (blue). E) TWEAK expression (red) in multinucleated
cells (indicated by arrows), and F) by plasma cells in tonsil tissue.
Expression of Fn14 (brown) in multinucleated cells (G), and blood
vessels of the synovial tissue (H), indicated by arrows. Sections
shown in E, F, G, and H were counterstained with haematoxylin.
Images shown in B and C were obtained with obj ×10; image
shown in A obtained with obj ×20, D, F, G, H with obj ×40 and E
with obj ×60.
Figure 4 TWEAK expression by PBMC. PBMC from two healthy
volunteers were sorted by FACS based on their expression of CD22,
yielding CD22
+ and CD22
- populations of greater than 94% purity
based on post-sort analysis (A). Isolated cells were then analysed for
TWEAK mRNA expression relative to that of GAPDH, by real-time RT-
PCR (B). Data shown are means of triplicate reactions ± SD.
Differences in relative expression of TWEAK mRNA between CD22
+
and CD22
- populations were tested by Student’s t-test (**P < 0.001).
Figure 5 Levels of soluble TWEAK in synovial fluids from
patients with RA and OA. Scatter plot of sTWEAK levels in the
synovial fluids obtained from active RA (n = 17) and OA (n = 16).
Horizontal lines reflect mean values of sTWEAK level in each group.
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expression was induced on a population of osteoblasts
expressing the immature osteoblast marker, STRO-1
(Figure 7). Together, these findings are consistent with
the induction by TWEAK of a pro-osteoclastogenic
osteoblastic phenotype.
Discussion
The findings of this study are consistent with the grow-
ing evidence that TWEAK is a mediator of the joint
destruction both in animal models of RA [10,11] and in
human RA [12]. Recently, a number of cell types
involved in the pathogenesis of RA have been reported
to express TWEAK and its receptor, Fn14. While syno-
vial fibroblasts from human patients with active RA
have been reported to express TWEAK and Fn14 [14]
another report demonstrated TWEAK expression by an
unidentified CD45-positive haemopoietic cell population
and Fn14 expression by both CD45-positive and -nega-
tive cells [12]. In contrast, van Kuijk and co-workers
[14] reported TWEAK/Fn14 expression by macrophages
but not by lymphocytes. The current study demonstrates
that several cell types in RA synovial tissue express
TWEAK, including CD68-positive macrophages, con-
firming the results of van Kuijk and co-workers [14].
Interestingly and in contrast to van Kuijk and co-work-
ers, we observed that a sub-population of CD22-positive
B lymphocytes and CD-38 positive plasma cells found in
lymphocyte aggregates in the sub-lining synovial tissues
expressed TWEAK. Our findings are consistent with
those of Kraan and coworkers who found that the num-
bers of CD38
+ plasma cells and CD22
+ B cells in RA
were the best discriminating markers when comparing
RA to non-RA inflammatory synovial samples [22].
In the current study, TWEAK expression by plasma
cells is in agreement with our recent finding that
demonstrated the expression of TWEAK in bone mar-
row plasma cells in patients with multiple myeloma
[18]. In that study, serum levels of TWEAK correlated
with the serum bone resorption marker, b-crosslaps,
and levels of the osteoclast recruitment chemokine,
CXCL12, strongly implying a pathological role for
plasma cell-derived TWEAK in bone erosion associated
with multiple myeloma [18]. In the current study, we
found that the TWEAK-positive B-Lymphocytes in the
germinal centres of normal tonsil sections were rare,
consistent with the infrequency of CD22
+ B cells at this
site [29]. While the CD22
+TWEAK
+ expressing B cells
may be a specific population associated with the chronic
inflammation seen in RA, CD22-positive B lymphocytes
isolated from human normal peripheral blood also
expressed abundant levels of TWEAK mRNA, suggest-
ing that B-lineage cells are a source of TWEAK. Based
o no u rf i n d i n g si nm u l t i p l em y e l o m a[ 1 8 ]t h e s ec e l l s
Figure 6 Effect of soluble TWEAK on osteoclast formation and
function. Human unfractionated PBMC were cultured for nine days
in medium containing rhM-CSF only (25 ng/ml) (A), M-CSF and
rhTWEAK at 100 ng/ml (B), 400 ng/ml (C) or 800 ng/ml (D), M-CSF
and rhRANKL (50 ng/ml) (E), or all of M-CSF (25 ng/ml), RANKL (50
ng/ml) and TWEAK (100 ng/ml) (F). Cultures were then fixed and
stained for TRAP. (G) Multinucleated cells (MNC), containing >3
nuclei, positive for TRAP, were counted from quadruplicate wells.
Data are expressed as means ± standard deviation. Significant
differences were determined by one way analysis of variance
(ANOVA) with Tukey post-hoc test:
a indicates difference to M-CSF
only control (P < 0.001) and
b denotes difference to M-CSF+RANKL
treatment (P < 0.05). (H) PBMC were seeded onto dentine slices in
the presence of rhM-CSF (25 ng/ml) with the addition of rhRANKL
(50 ng/ml) and/or rhTWEAK as indicated. Resorption was assessed
after 14 days of culture by SEM and is expressed as the mean ± SD
resorption expressed as a percentage of that measured for the
RANKL/M-CSF control. Data shown are pooled from two
independent experiments with resorption assessed for four dentine
slices/treatment/donor. No significant differences were observed
between RANKL treatments.
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characteristic of RA. Interestingly, an immunotherapeu-
tic approach that targets CD22, epratuzumab, has
proved efficacious in the treatment of non-Hodgkin
lymphoma, and in the autoimmune diseases, systemic
lupus erythematosus and primary Sjögren’ss y n d r o m e
[30]. Our findings suggest that CD22 and CD38 are also
potential therapeutic targets in RA.
We were unable to verify the cell types expressing Fn14
using dual label IHC for technical reasons; however, many
of these cells also had the morphology of lymphocytes and
monocytes and importantly our observation indicates that
Fn14 was strongly expressed by multinucleated cells
within the synovial tissue. We have previously demon-
strated that these multinucleated cells were preosteoclasts
[31]. It is well known that the active rheumatic joint con-
tains an influx of osteoclast precursors [31]. This is also
consistent with a recent study by our group demonstrating
the expression of TWEAK and Fn14 by multinucleated
cells in gingival tissues from chronic periodontitis patients
[32]. This would suggest that TWEAK-Fn14 signalling
may stimulate osteoclastogenesis and hence could contri-
bute to the bone loss associated with chronic inflamma-
tory diseases [10,11].
The observation that Fn14 is expressed by cells asso-
ciated with blood vessels is consistent with the report
that TWEAK regulates human endothelial cell prolifera-
tion, migration and survival in vitro [33,34]. Both
TWEAK and Fn14 expression was associated with syno-
vial tissue blood vessels suggesting that TWEAK has an
autocrine effect on the angiogenesis seen in RA synovial
tissue. Furthermore, this is consistent with the perivas-
cular expression of TWEAK and Fn14 expression in RA
and psoriatic synovial tissue [14].
A significant decrease in serum TWEAK has been
reported in RA patients responding to treatment with
etanercept [13,14] while persistent TWEAK/Fn14
expression was seen in a RA patient cohort receiving
infliximab treatment [14] suggesting a role for TWEAK
in modulation of disease activity. Our data demonstrated
significantly lower expression of TWEAK in the inactive
RA synovial tissues. In the majority of patients this
followed successful non-TNF targeted DMARD treat-
ment, suggesting that DMARDs may reduce TWEAK
Figure 7 Effect of soluble TWEAK on cell surface RANKL expression by STRO-1 osteoblast subpopulation. Human primary osteoblasts
were cultured untreated or treated with rhTWEAK (50 ng/ml) for three days, harvested by collagenase/dispase digestion and stained for STRO-1
and RANKL expression. Stained cells were analysed by FACS. The percentage of cells present in each of the four sub-populations is indicated.
Data are presented for two independent donors’ cells.
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Higher TWEAK expression in active RA was also
reflected in the increased synovial fluid levels of
sTWEAK compared with those in OA in our study.
Based on this, we suggest that monitoring the sTWEAK
levels in synovial fluids could possibly be another mar-
ker of disease progression.
It was previously reported that TWEAK stimulates the
differentiation of RAW 264.7 monocyte/macrophage
cells into functional osteoclasts, and did so in the
absence of Fn14 expression [17]. However, we could not
reproduce these findings in vitro using recombinant
TWEAK to directly stimulate osteoclast formation from
RAW 264.7 cells, or from human PBMC, either unfrac-
tionated or sorted on the basis of CD14 expression, a
fraction shown previously to contain the osteoclast pre-
cursor [25,35]. Although the present study demonstrated
that multinucleated cells expressed Fn14, our data indi-
cate that the stimulation of osteoclast formation by
TWEAK may not be due to a direct interaction with
osteoclast precursors. However, we have demonstrated
that stromal osteoblasts express Fn14 and are sensitive
to the effects of TWEAK [10,16], including the induced
expression of RANKL and CXCL12 mRNAs [18]. This
supports an indirect role for TWEAK in recruiting and
generating osteoclasts, via the osteoblast. In the current
study we confirmed that TWEAK induced the expres-
sion of cell surface RANKL protein and did so in a
population of human osteoblasts expressing the imma-
ture osteoblast cell surface marker, STRO-1, cells we
have previously demonstrated are capable of supporting
osteoclastogenesis [36]. This is reminiscent of our earlier
study, in which RANKL mRNA expression was prefer-
entially induced in STRO-1-positive osteoblasts in
response to 1a,25-dihydroxyvitaminD3 [37]. In addition,
we recently reported a novel role for TWEAK in the
regulation of osteoblast differentiation [16] and showed
that TWEAK, and the combination of TWEAK and
TNFa, induced the expression of sclerostin, a negative
regulator of bone formation [38], and as we recently
demonstrated [39], human osteoblast differentiation and
matrix mineralization. Thus, the elevated TWEAK
expression we see in RA may not only stimulate bone
resorption by osteoclasts by induction of RANKL on
osteoblasts but also inhibit new bone formation, contri-
buting to the reduction in bone mass observed in
inflammatory bone disease [40].
Conclusions
The current study found high levels of TWEAK expres-
sion in synovial tissues and synovial fluids from patients
with active RA. Together with its ability to induce cell
surface expression of RANKL by osteoblasts and possi-
bly induce activation of B cells into plasma cells we
postulate that TWEAK in this context would be pro-
osteoclastogenic and would thus contribute to the bone
loss associated with this chronic inflammatory disease.
These findings support the concept that TWEAK should
be considered as a therapeutic target in RA.
Abbreviations
ACR: American College of Rheumatology; AEC: 3,9 aminoethylcarbazole; CIA:
collagen induced arthritis; DAB: diaminobenzidine; DAS28: disease activity
score; DMARD: disease modifying anti-rheumatic drug; FACS: fluorescence
activated cell sorting; FCS: foetal calf serum; HRP: horse raddish peroxidase;
HUVEC: human umbilical vein endothelial cells; IHC: immunohistochemistry;
MAb: monoclonal antibody; MAPK: mitogen-activated protein kinases; MMP:
matrix metalloproteinase; OA: osteoarthritis; PBMC: peripheral blood
mononuclear cells; PBS: phosphate buffered saline; RA: rheumatoid arthritis;
RANKL: Receptor activator of NF Kappa B Ligand; rh: recombinant human;
SQA: semi-quantitative assessment; TMB: tetramethylbenzidine; TNF: Tumor
necrosis factor; TRAP: tartrate resistant acid phosphatase; TWEAK: TNF-like
weak inducer of apoptosis.
Acknowledgements
This work has been supported in part by grants from the Australian National
Health and Medical Research Council [ID 453568 to D.R.H]; C.J Martin
Fellowship [ID299078 to T.C] and NHMRC R. Douglas Wright Fellowship to G.
J.A.
The authors thank Dr. Peter Diamond, Myeloma Research Laboratory, for
performing CD22 cell sorts, and Renee Ormsby, Bone Cell Biology Group, for
performing real-time RT-PCR. We express our gratitude to Dale Caville,
Discipline of Anatomy and Pathology, The University of Adelaide for his
photographic expertise.
Author details
1Discipline of Anatomy and Pathology, School of Medical Sciences,
University of Adelaide, Frome Road, Adelaide, SA 5005, Australia.
2Rheumatology Research Unit, Repatriation General Hospital, Daws Road,
Adelaide, SA 5041, Australia.
3Myeloma Research Laboratory, Bone and
Cancer Laboratories, Division of Haematology, Institute of Medical &
Veterinary Science, Frome Road, Adelaide, SA 5005, Australia.
4Immunology,
Biogen Idec Inc., Cambridge Centre, Cambridge, MA 02142, USA.
5Bone Cell
Biology Group, Discipline of Orthopaedics and Trauma, University of
Adelaide, Frome Road, Adelaide, SA 5005, Australia.
6Hanson Institute, Frome
Road, Adelaide, SA 5005, Australia.
Authors’ contributions
AD played a major role in manuscript preparation, experimental work,
statistical analysis and interpretation and MS directed patient recruitment
and assessment and critical revision of the manuscript. TC carried out ELISA
assays and analysis of ELISA data and wrote the manuscript. CAH and CV
were substantially involved in in vitro assays. ACWZ was involved in
experimental design and critical analysis of the manuscript. TSZ and DMF
were involved in critical analysis of the manuscript. HMW. identified
appropriate patient tissues available for the study. GJA initiated the project
and was substantially involved in experimental design and critical analysis of
the manuscript. DRH coordinated the project and was involved in critical
revision of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 October 2010 Revised: 13 February 2011
Accepted: 24 March 2011 Published: 24 March 2011
References
1. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS: TWEAKing
tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14
pathway in health and disease. Cytokine 2007, 40:1-16.
2. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: discovery, biology
and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
Dharmapatni et al. Arthritis Research & Therapy 2011, 13:R51
http://arthritis-research.com/content/13/2/R51
Page 9 of 103. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA: The Fn14
cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors
1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J
2003, 371:395-403.
4. Campbell S, Michaelson J, Burkly L, Putterman C: The role of TWEAK/Fn14
in the pathogenesis of inflammation and systemic autoimmunity. Front
Biosci 2004, 9:2273-2284.
5. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, Hwang K, Young Lee S: TNF-
related weak inducer of apoptosis receptor, a TNF receptor superfamily
member, activates NF-kappa B through TNF receptor-associated factors.
Biochem Biophys Res Commun 2003, 305:789-796.
6. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, Zheng T,
Schiffer L, Michaelson JS, Putterman C: Proinflammatory effects of TWEAK/
Fn14 interactions in glomerular mesangial cells. J Immunol 2006,
176:1889-1898.
7. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K: Pro-
inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein
endothelial cells. Biochem Biophys Res Commun 2002, 299:488-493.
8. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory
effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK)
on human gingival fibroblasts. Clin Exp Immunol 2006, 146:540-549.
9. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB,
Ambrose C, Dayer JM: Proinflammatory activity of TWEAK on human
dermal fibroblasts and synoviocytes: blocking and enhancing effects of
anti-TWEAK monoclonal antibodies. Arthritis Res 2002, 4:126-133.
10. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L,
Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS,
Hess H: TWEAK is a novel arthritogenic mediator. J Immunol 2006,
177:2610-2620.
11. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H,
Okumura K: Involvement of TNF-like weak inducer of apoptosis in the
pathogenesis of collagen-induced arthritis. J Immunol 2006,
177:6433-6439.
12. Kamijo S, Nakajima A, Kamata K, Kurosawa H, Yagita H, Okumura K:
Involvement of TWEAK/Fn14 interaction in the synovial inflammation of
RA. Rheumatology (Oxford) 2008, 47:442-450.
13. Park MC, Jung SJ, Park YB, Lee SK: Relationship of serum TWEAK level to
cytokine level, disease activity, and response to anti-TNF treatment in
patients with rheumatoid arthritis. Scand J Rheumatol 2008, 37:173-178.
14. van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP:
TWEAK and its receptor Fn14 in the synovium of patients with
rheumatoid arthritis compared to psoriatic arthritis and its response to
TNF blockade. Ann Rheum Dis 2009, 69:301-304.
15. Xia LP, Xiao WG, Li JS, Ding S, Lu J: Effects of TWEAK on the synthesis of
MMP-3 in fibroblast-like synoviocytes of rheumatoid arthritis. Xi Bao Yu
Fen Zi Mian Yi Xue Za Zhi 2009, 25:46-48.
16. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR,
Fazzalari NL, Evdokiou A, Atkins GJ: Pro-inflammatory cytokines TNF-
related weak inducer of apoptosis (TWEAK) and TNFalpha induce the
mitogen-activated protein kinase (MAPK)-dependent expression of
sclerostin in human osteoblasts. J Bone Miner Res 2009, 24:1434-1449.
17. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T: TWEAK mediates signal
transduction and differentiation of RAW264.7 cells in the absence of
Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003,
278:32317-32323.
18. Williams SA, Martin SK, Vincent C, Gronthos S, Zheng T, Atkins GJ,
Zannettino AC: Circulating levels of TWEAK correlate with bone erosion
in multiple myeloma patients. Br J Haematol 2010, 150:373-376.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS,
Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
20. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W,
Cooke TD, Greenwald R, Hochberg M, et al: Development of criteria for
the classification and reporting of osteoarthritis. Classification of
osteoarthritis of the knee. Diagnostic and Therapeutic Criteria
Committee of the American Rheumatism Association. Arthritis Rheum
1986, 29:1039-1049.
21. Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, Kraan M,
Coleman M, Ahern MJ: Microarchitecture and protective mechanisms in
synovial tissue from clinically and arthroscopically normal knee joints.
Ann Rheum Dis 2003, 62:303-307.
22. Kraan MC, Haringman JJ, Post WJ, Versendaal J, Breedveld FC, Tak PP:
Immunohistological analysis of synovial tissue for differential diagnosis
in early arthritis. Rheumatology (Oxford) 1999, 38:1074-1080.
23. Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ,
Weedon H, Chen P, Screaton G, Xu XN, Haynes DR: Elevated expression of
caspase-3 inhibitors, survivin and xIAP correlates with low levels of
apoptosis in active rheumatoid synovium. Arthritis Res Ther 2009, 11:R13.
24. Gomori E, Pal J, Abraham H, Vajda Z, Sulyok E, Seress L, Doczi T: Fetal
development of membrane water channel proteins aquaporin-1 and
aquaporin-4 in the human brain. Int J Dev Neurosci 2006, 24:295-305.
25. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM,
Evdokiou A, Zannettino AC: RANK expression as a cell surface marker of
human osteoclast precursors in peripheral blood, bone marrow, and
giant cell tumors of bone. J Bone Miner Res 2006, 21:1339-1349.
26. Vincent C, Kogawa M, Findlay DM, Atkins GJ: The generation of osteoclasts
from RAW 264.7 precursors in defined, serum-free conditions. J Bone
Miner Metab 2009, 27:114-119.
27. Simmons PJ, Torok-Storb B: Identification of stromal cell precursors in
human bone marrow by a novel monoclonal antibody, STRO-1. Blood
1991, 78:55-62.
28. Atkins GJ, Welldon KJ, Halbout P, Findlay DM: Strontium ranelate
treatment of human primary osteoblasts promotes an osteocyte-like
phenotype while eliciting an osteoprotegerin response. Osteoporos Int
2008, 20:653-664.
29. Nitschke L: The role of CD22 and other inhibitory co-receptors in B-cell
activation. Current Opinion in Immunology 2005, 17:290.
30. Dorner T, Goldenberg DM: Targeting CD22 as a strategy for treating
systemic autoimmune diseases. Ther Clin Risk Manag 2007, 3:953-959.
31. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM:
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand
(RANKL) regulate osteoclast formation by cells in the human rheumatoid
arthritic joint. Rheumatology (Oxford) 2001, 40:623-630.
32. Kataria N, Bartold PM, Dharmapatni AASK: Expression of tumor necrosis
factor-like weak inducer of apoptosis (TWEAK) and its receptor,
fibroblast growth factor-inducible 14 protein (Fn14), in healthy tissues
and tissues affected by periodontitis. J Periodontal Res 2010, 45:564-573.
33. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR: TWEAK induces
angiogenesis and proliferation of endothelial cells. J Biol Chem 1999,
274:8455-8459.
34. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J,
Thangada S, Hla T, Williams MS, Winkles JA: TWEAK is an endothelial cell
growth and chemotactic factor that also potentiates FGF-2 and VEGF-A
mitogenic activity. Arterioscler Thromb Vasc Biol 2003, 23:594-600.
35. Nicholson GC, Malakelis M, Collier FM, Cameron PU, Holloway W, Gough TJ,
Gregorio-King C, Kirkland MA, Myers DE: Induction of osteoclast from
CD14-positive human peripheral blood mononuclear cells by activator
of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond) 2000, 99:133-140.
36. Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC:
Human trabecular bone-derived osteoblasts support human osteoclast
formation in vitro in a defined, serum-free medium. J Cell Physiol 2005,
203:573-582.
37. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K,
Findlay DM, Zannettino AC: RANKL expression is related to the
differentiation state of human osteoblasts. J Bone Miner Res 2003,
18:1088-1098.
38. Paszty C, Turner CH, Robinson MK: Sclerostin: a gem from the genome
leads to bone-building antibodies. J Bone Miner Res 2010, 25:1897-1904.
39. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby RT, Wijenayaka AR,
Zelenchuk L, Evdokiou A, Findlay DM: Sclerostin is a locally acting
regulator of late-osteoblast/pre-osteocyte differentiation and regulates
mineralization through a MEPE-ASARM dependent mechanism. J Bone
Miner Res 2011.
40. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB,
Gravallese EM: Osteoblast function is compromised at sites of focal bone
erosion in inflammatory arthritis. J Bone Miner Res 2009, 24:1572-1585.
doi:10.1186/ar3294
Cite this article as: Dharmapatni et al.: TWEAK and Fn14 expression in
the pathogenesis of joint inflammation and bone erosion in
rheumatoid arthritis. Arthritis Research & Therapy 2011 13:R51.
Dharmapatni et al. Arthritis Research & Therapy 2011, 13:R51
http://arthritis-research.com/content/13/2/R51
Page 10 of 10